<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00627887</url>
  </required_header>
  <id_info>
    <org_study_id>ISRCTN40355220</org_study_id>
    <secondary_id>ISRCTN40355220</secondary_id>
    <nct_id>NCT00627887</nct_id>
  </id_info>
  <brief_title>Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression</brief_title>
  <official_title>Randomised Controlled Trial of Electroconvulsive Therapy (ECT) With Pharmacotherapy or Pharmacotherapy Alone in Relapse Prevention of Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro County Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala-Örebro Regional Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Örebro County Council</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if continuation electroconvulsive therapy (ECT) is
      safe and effective in relapse prevention of depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized multicenter clinical trial with two parallel groups. Patients with major
      depression (unipolar or bipolar), who have remitted with electroconvulsive therapy (ECT) are
      eligible. All patients receive pharmacotherapy (venlafaxine target dose 300mg/day, and
      lithium target dose 0,5-0,8 mmol/L). The intervention is continuation unilateral ECT weekly
      for the first 6 weeks thereafter every 2 weeks for one year. Depressive relapse is the
      primary outcome measure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS &gt;20, psychiatric hospitalization or suicide</measure>
    <time_frame>1 year, all patients assessed if MADRS-S &gt; 20 and at 2,6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Examination</measure>
    <time_frame>2,6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAS-cog</measure>
    <time_frame>2,6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autobiographical Memory Inventory -Short Form (AMI-SF)</measure>
    <time_frame>2,6 and 12 months patients treated in Örebro</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity</measure>
    <time_frame>2,6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Udvalg for Kliniske Undersogelser (UKU)</measure>
    <time_frame>2, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS-S Montgomery Asberg Depression Rating scale- self assessment</measure>
    <time_frame>weekly for 6 weeks thereafter every 2 weeks for a total of one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>ECT+pharmacotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pharmacotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electroconvulsive therapy</intervention_name>
    <description>unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year</description>
    <arm_group_label>ECT+pharmacotherapy</arm_group_label>
    <other_name>ECT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
    <description>extended release target dose of 300mg/day duration of one year</description>
    <arm_group_label>ECT+pharmacotherapy</arm_group_label>
    <arm_group_label>pharmacotherapy</arm_group_label>
    <other_name>Efexor</other_name>
    <other_name>Effexor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>serum concentration 0,5-0,8 mmol/L, one year duration</description>
    <arm_group_label>ECT+pharmacotherapy</arm_group_label>
    <arm_group_label>pharmacotherapy</arm_group_label>
    <other_name>Lithionit</other_name>
    <other_name>Lithobid</other_name>
    <other_name>Eskalith</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. MINI-PLUS verified major depressive episode (unipolar or bipolar).

          2. ECT within the last 3 weeks.

          3. Either Remission defined as MADRS &lt; 10 or

          4. Response defined as MADRS &lt; 15 combined with patient assessed CGI-I of at least much
             improved

        Exclusion Criteria:

          1. Schizophrenia or Schizoaffective disorder

          2. Addiction or Dependence

          3. Kidney disease that contraindicates lithium treatment

          4. Vascular or heart disease that contraindicates venlafaxine treatment

          5. Uncontrolled Epilepsia

          6. Age less that 18

          7. Pregnancy or Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingemar Engstrom, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>County Council of Orebro, University of Orebro, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Axel Nordenskjold, MD</last_name>
    <role>Study Director</role>
    <affiliation>County Council of Orebro,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars von Knorring, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>County Council of Uppsala, University of Uppsala Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatric Clinic</name>
      <address>
        <city>Sater</city>
        <state>Dalarna</state>
        <zip>78327</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric clinic</name>
      <address>
        <city>Orebro</city>
        <zip>70116</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Löwenströmska sjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>11000</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Clinic</name>
      <address>
        <city>Uppsala</city>
        <zip>75017</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, Rasmussen K, Mueller M, Bernstein HJ, O'Connor K, Smith G, Biggs M, Bailine SH, Malur C, Yim E, McClintock S, Sampson S, Fink M. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006 Dec;63(12):1337-44.</citation>
    <PMID>17146008</PMID>
  </reference>
  <reference>
    <citation>Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001 Mar 14;285(10):1299-307.</citation>
    <PMID>11255384</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro County Council</investigator_affiliation>
    <investigator_full_name>prof Ingemar Engström</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depressive Disorder, Major</keyword>
  <keyword>Electroconvulsive Therapy</keyword>
  <keyword>Lithium Carbonate</keyword>
  <keyword>venlafaxine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

